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At presentation, copeptin and highly sensitive troponin levels were 
significantly higher in AMI patients compared to levels in patients with 
other diagnosis (p<0.01). The negative predictive value of copeptin was 
94.8% in this population. There was no significant difference between 
the diagnostic accuracy of the 3 markers as quantified by the area under 
receiver-operating characteristic curve (AUROC) for copeptin, 0.89 (95% 
confidence interval [CI] 0.80 to 0.92) vs Roche High-Sensitive Troponin 
T 0.82 (95% CI 0.73 to 0.92) vs Siemens Troponin I Ultra 0.79 (95% CI 
0.64 to 0.94) (p>0.05).
Six hours later, the analysis of troponin levels variations improved the dia-
gnostic accuracy of AMI with an AUROC for Roche High-Sensitive Troponin 
T at 0.95 (95%CI, 0.85 to100) and for Siemens Troponin I Ultra at 0.99 
(95%CI 0.98 to 1.00) (p<0.01).
Conclusion: The use of copeptin seems to allow a rapid rule out of AMI at 
presentation.  Highly sensitive troponins assays are likely to improve the rapid 
management of chest pain. Nevertheless, regarding clinical care, the loss of 
speci¿ city should lead to decision threshold adjustment.
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Purpose: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inÀ am-
matory biomarker secreted in the atherosclerotic plaque. Aim of our study was 
to explore possible links between Lp-PLA2, cardiac disease and treatments.
Methods: Subjects (494 patients aged 64.2±16.7y) were recruited from 
a population scheduled for diagnostic coronary arteriography,. All patients 
underwent routine clinical parameters, cardiac and biological evaluation. 
Lp-PLA2 was measured in serum with a Plac® test turbidimetric immunoassay 
(diaDexus).
Control values were measured from 61 healthy subjects aged 44.5±17.6y 
(25-59) without cardiovascular risk factors nor cardiac treatment.
Results: In healthy controls, mean Lp-PLA2 was 163±43 Pg/L (men 
166±45; women 159±39, NS).
Etiologies of cardiomyopathies (CM) were ischemic, valvular, cardiac 
failure with LV dysfunction, infection and aorta aneurysm. Lp-PLA2 levels 
were 216±17Pg/L and varied with CM (Table). Lp-PLA2 correlated with age, 
BMI, current smoking, history of HBP, total cholesterol, LDL-c and apoB but 
not with Lp(a), diabetes, creatininemia or NYHA status and sex. Lp-PLA2 
was also signi¿ cantly associated with treatments such statins and ACEi but not 
with b-blockers, antiaggregant therapy or diuretics.
Table: Lp-PLA2 levels (mean±SD, *=baseline value vs Controls) 
Age (y) Lp-PLA2 (Pg/L) P
Controls (n=61) 44.5±17.6 163±43
Ischemic CM 
(n=143)
64.9±10.9 220.4±51.9 0.001*
HF (n=133) 59.0±15.5 256.3±46.1 <0.0001*
Aortic aneurysm 60.8±12.4 218.1±38.9 0.003*
Sepsis 66.6±13.0 226.7±47.3 <0.002*
Conclusion: Our principal ¿ ndings had practical implications as interpre-
tation of Lp-PLA2 levels needs to know cardiac parameters as well as symp-
toms and clinical status but also treatments (statins and ACEi). 
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Background: The rapid rule out of acute myocardial infarction (AMI) is 
a major unmet clinical need. Copeptin, as a marker of endogenous stress and 
highly sensitive troponins assays may be useful in this setting.
Methods: In 80 consecutive patients (age 62±15, male 75%) presenting to 
our chest pain unit (CPU) with AMI suggestive symptoms, and a ¿ rst mea-
surement of standard troponin assay <0.05g/L, we measured copeptin level 
(Brahms) at presentation, and those of two different sensitive assays (Roche 
High-Sensitive Troponine T, Siemens Troponin I ultra) at presentation and 6 
hours later. We then compared the copeptin and sensitive troponins results 
according to the diagnosis adjudicated by cardiologists.
Results: AMI was considered as the ¿ nal diagnosis in 10 patients (12.5%).
0
0
0,1
0,1
0,2
0,2
0,3
0,3
0,4
0,4
0,5
0,5 0,6 0,7 0,8 0,9 1
0,6
0,7
0,8
0,9
1
Specificity
Se
ns
itiv
ity
Se
ns
itiv
ity
At presentation
non discrimuan
copeptin
ints
inths
1
Specificity
Se
ns
itiv
ity
6 hours later
0
0
0,1
0,1
0,2
0,2
0,3
0,3
0,4
0,4
0,5
0,5 0,6 0,7 0,8 0,9 1
0,6
0,7
0,8
0,9
1
▼ ▼
01_corpus_ok.indd   46 26/04/2011   15:50:10
Archives of Cardiovascular Diseases Supplements (2011) 2, 1-91 47
© Elsevier Masson SAS. All rights reserved.
Results (Table 1): Our results show that the NGAL value is statisti-
cally higher than the cut-off in dehydrated patients: 222,32 versus 132,76 ng/
mL.
In addition, our results indicate that the average value of the age, Serum 
Creatinine and BNP are not statistically different in these groups.
Perspectives: These results clearly show that the evaluation of the NGAL 
level would help clinicians to identify early dehydration with AKI risk in the 
elderly.
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Introduction: Extubation of patients with heart failure may put them at 
risk for aggravation. Heart failure is associated with increased ventricular 
afterload. As brain natriuretic peptide (BNP) rises in the presence of increased 
afterload, it is supposed to rise after extubation. The aim of this study was to 
evaluate pre-extubational BNP as a predictor for post-extubational circulatory 
complications due to elevated afterload.
Methods: In 60 newborns after switch operation with left heart insuf¿ -
ciency, circulatory, respiratory, metabolic parameters and BNP were mea-
sured before and after extubation under conditions of minimal handling and 
unchanged treatment. They were compared for different pre-extubational BNP 
levels and BNP post-extubational dynamics. A BNP cut-off point was calcu-
lated for the prediction of post-extubational complications.
Results: BNP increased from pre-extubational 554.5 to post-extubational 
1165 pg/ml. Clinical data remaining unchanged, pH and base excess as subs-
trata for reduced cardiac output due to higher afterload decreased from 7.41 
to 7.38 and from 1.5 to -0.05 mval/l, respectively (p<0.001).  Sensitivity for 
pre-extubational BNP as predictor of base excess decrease was 80.4%, its 
speci¿ city 92.9%, with a cut-off point at 384 pg/ml. Absolute BNP increase 
was higher if pre-extubational BNP was higher (r=0.77), relative increase 
was highest for pre-extubational BNP under the cut-off point. Base excess 
decreased signi¿ cantly for BNP beyond the cut-off but not below.
Conclusions: BNP measured before extubation can help to screen patients 
at risk for important changes in left ventricular afterload and subsequent signs 
of heart insuf¿ ciency after extubation.    
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Objectives: Soluble epoxide hydrolase (sEH) inhibition, which increases 
epoxyeicosatrienoic acids concentrations, affords cardiovascular protection in 
hypertension, but whether this latter occurs in chronic heart failure (CHF) is 
unknown. We sought the impact of sEH inhibition on left ventricular (LV) 
function in CHF.
Methods: In rats with CHF, LV function, perfusion and remodeling were 
assessed using MRI and invasive hemodynamics after long-term (42 days star-
ting 8 days after coronary ligation) and short-term (3 days starting 47 days 
after coronary ligation) treatment with the sEH inhibitor AUDA (twice 
0.25 mg.kg-1.day-1).
Results: Long- and short-term sEH inhibition, demonstrated by the 
increased plasma epoxyeicosatrienoic acids level, increased cardiac output 
without modifying arterial blood pressure, resulting in a reduced total 
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Approximately 20% of heart failure patients have low levels of serum 
sodium, often at a time when they are hospitalized during a period of decom-
pensation. It may reÀ ect worsening heart failure and the deleterious effects of 
activation of neurohormones. However, impact of hypernatremia, prognosti-
cally relevant cut-off values, and differential prognosis with reference range 
serum sodium levels are not well de¿ ned.
Methods: Our aim was to prospectively assess the impact of baseline 
n atremia and changes in sodium level during median follow-up of 32 months 
in 1509 patients. According to our central laboratory, hypo- and hypernatremia 
were de¿ ned as sodium levels <135 and >145 mmol/l. Chi2 test was used, a 
difference was statistically considered signi¿ cant if p<0.05.
Results: The prevalence of Hyponatremia was 12.45% and hypernatremia 
was 0.9%. The mean age was 64.32 years (20-97), with a male predominance 
(68.15%).There was a correlation between value of sodium levels and severity 
of heart failure. The positive correlates of hyponatremia compared with normo-
natremia were NYHA functional class [we ¿ nd class III in 32.9% patients vs 
18.5% (p=0,0089) and class IV in 7.9% vs 2.09% (p=0,0075)], decompensa-
tion found in 26.5% patients vs 12.04% (p= 0,0085), renal dysfunction: mean 
creatinine was at 15 vs 10mg per litre (p=0.0015), use of high dose of diure-
tics 61.17% vs 40.46% (p=) and use of spironolactone 81,38% vs 51,50% (p=). 
Positive correlates of hypernatremia were intake of diuretics 54.8% vs 40.46% 
(p=), NYHA functional class [72.78% were in class II vs 61.03% and 27.22% 
were in class III vs 18.5% (p= )], decompensation in 38.8% vs12.04% (p= )
Conclusion: The severity of heart failure, the renal function and medication 
were associated with serum sodium levels. Our data indicate the need of further 
research into optimized management of sodium-water homeostasis in heart failure.
0105
Is NGAL(Neutrophil Gelatinase-Associated Lipocalin) a biomarker of 
dehydration in elderly patients with heart failure?
Michele Escande [Orateur] (1), Marta Mordarska (1), Lilit Marsoubian (1), 
Nathalie Esande Beillard (2), Emmanuel Beillard (3)
(1) CHG louis Brunet, cardiogériatrie, Allauch, France – (2) Institute of 
medical Biology Biopolis, BIology, Singapore, Singapour – (3) DUKE-NUS 
Medical School, BIology, Singapore, Singapour
Rationale: In elderly dehydrated patients (Age >80 years), the early detec-
tion and prevention of acute kidney injury (AKI) and acute heart failure (AHF) 
is important but dif¿ cult.  The diagnostic and prognostic value of NGAL, an 
early biomarker of AKI, has not been evaluated, in comparison to serum crea-
tinine, which is a biomarker of  Glomerular Filtration Rate (GFR )
Methodology: A total of 60 consecutive high risk patients  with Heart 
Failure,admitted 2009 in a CardioGeriatric Unit,were divided into 2 groups 
according the presence of clinical dehydration.
We compared by a Student unpaired T test the mean value of the age, 
Creatinine (mg/L), BNP(cut-off>100pg/mL), NGAL (cut-off>149 ng/mL) by 
triage test and DFG by MDRD ( cut-off<40/mL/mn/ 1,73m2) (Table 1).
Table 1
Dehydration No dehydration
N 31 29 
Mean Age 84,77 83,10
NGAL 222,32 132,76
Creatinine 18,19 14,72
MDRD 60,66
BNP 459,76 533,24 
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Background: Telomeres are structures composed of DNA repeats that 
protect the end of chromosomes, but shorten with each cell division. 
Previous studies have demonstrated a relationship between leucocytes telo-
mere length (LTL), health and longevity. An association between LTL and 
cardiovascular diseases, including left ventricular dysfunction and acute 
myocardial infarction (MI) has been found. We aimed to investigate the 
relationship between LTL and left ventricular ejection fraction (LVEF) in 
patients with acute MI.
Patients and methods: LTL was assessed by QPCR method from circu-
lating leukocytes of 174 consecutive patients admitted <24H after symptom 
onset in intensive care unit for acute MI, with blood sampling on admission. 
LVEF was measured by echocardiography at 3±1 days after admission using 
the Simpson method.
Results: Most patients were male (75%), with a mean age at 66±14 years, 
and LVEF was 53±12%. Mean LTL was 1.28±0.12 T/S ratio. LTL was negati-
vely associated with age (r=-0.22, p=0.003), female gender, heart rate, current 
smoking, HDL-cholesterol and logNT-proBNP, but positively correlated with 
body mass index and LVEF (r=+0.21, p=0.007). Age-adjusted LTL was also 
associated with LVEF (p=0.028). Patients with altered LVEF (<40%) had 
lower LTL and age-adjusted LTL than patients with LVEF>40% (1.24±0.11 
vs 1.29±0.13 T/S, p=0.043 and 1.27±0.02 vs 1.28±0.19 T/S, p=0.021). By 
multivariate linear regression analysis, LTL remains signi¿ cantly associated 
with LVEF (B(SE): 15.6(7.3), p=0.028), even when adjusted for the confoun-
ding factors (age: E(SE): -0.12(0.1), p=0.052; dyslipidemia: E(SE): 4.1(1.7), 
p=0.019; prior MI: E(SE): -7.9(2.9), p=0.007; ST segment elevation MI: 
E(SE): -7.3(1.7), p<0.001)(R²=0.22).
Conclusions: Our results showed that, independently of other determinants 
of LVEF after acute MI, left ventricular dysfunction appears associated with 
TL shortening, suggesting that ageing directly inÀ uences cardiac function in 
the setting of an acute MI.
 peripheral resistance. Long- and short-term AUDA increased to the same 
extent LV end-systolic pressure-volume relation, but only long-term AUDA 
decreased LV end-diastolic pressure, LV relaxation constant Tau and LV 
end-diastolic pressure-volume relation, associated with a reduced LV dias-
tolic volume and LV collagen density. Short- and more markedly long-term 
AUDA increased LV tissue perfusion. Finally, short- and long-term AUDA 
decreased LV inducible NO-synthase expression, but increased endothelial 
NO-synthase expression and reduced- to oxidized glutathione ratio, associated 
with decreases in reactive oxygen species level and MMP-2 activity.
Conclusion: In experimental CHF, long-term sEH inhibition improves LV 
systolic and diastolic function. The latter probably involves effects already 
observed after short-term sEH inhibition i.e. increased myocardial tissue per-
fusion, reduced LV oxidative stress, peripheral vasodilatation, but also effects 
only observed after long-term sEH inhibition, i.e. reduced LV dilatation and 
collagen accumulation.
Keywords: heart failure, epoxyeicosatrienoic acids, soluble epoxide hydrolase.
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